\n<\/p>\n
\n Gastrointestinal Cancer Drug Developer Arbele Receives AFCR Investment Funding <\/p>\n
HONG KONG SAR – Media OutReach<\/a> – 8 April 2021 – Arbele<\/a> \u00a0<\/p>\n Arbele’s \u00a0<\/p>\n BRACE \u00a0<\/p>\n “The \u00a0<\/p>\n “It \u00a0<\/p>\n “With the BRACE Award \u00a0<\/p>\n “The BRACE Award \u00a0<\/p>\n The \u00a0<\/p>\n Learn Gastrointestinal Cancer Drug Developer Arbele Receives AFCR Investment Funding HONG KONG SAR – Media OutReach – 8 April 2021 – Arbele has been selected as the winner of the Asian Fund for Cancer Research’s (AFCR) inaugural BRACE Award Venture Competition, a first of its kind program for early stage oncology technology companies located in Asia …<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[60],"tags":[],"_links":{"self":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/13877"}],"collection":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/comments?post=13877"}],"version-history":[{"count":0,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/13877\/revisions"}],"wp:attachment":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/media?parent=13877"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/categories?post=13877"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/tags?post=13877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nhas been selected as the winner of the Asian Fund for Cancer Research’s (AFCR)<\/a>
\ninaugural BRACE
\nAward Venture Competition<\/a>, a first of its kind
\nprogram for early stage oncology technology companies located in Asia or
\nfocused on cancers prevalent among Asian communities. As a result of its win,
\nthe Hong Kong-based company has received US$300,000 in AFCR investment. <\/p>\n
\nBRACE Award Venture Competition win is the result of a rigorous review and
\nevaluation process led by two blue ribbon committees convened by AFCR. One committee,
\nin fall 2020, judged the start-up and its tumor-fighting technology as among
\nthe strongest of eight semi-finalists in a 6 November event; and the other
\ncommittee, in winter 2020\/2021, determined the company as most likely to make a
\ndifference for cancer patients and produce a positive return on investment from
\namong the prior-chosen finalists.<\/p>\n
\nAward Venture Competition winners can apply AFCR’s investment toward obtaining
\ncritical research data and pre-clinical results, as well as attract larger,
\nfollow-on investors. Such benefits give participating start-ups a much better
\nchance of delivering technologies likely and able to benefit cancer patients.
\nWhile future positive returns to AFCR on its US$300,000 investment will be
\napplied by the non-profit organization toward its cancer research funding and
\neducation programming.\u00a0 <\/p>\n
\nBRACE Award Venture Competition is making a real difference in funding not only
\nearly stage, risk-taking companies in Asia that are battling cancer, but also
\nstart-ups that are tackling Asia-prevalent forms of the disease,” stated Arbele
\nChief Executive Officer John
\nLuk, DMedSc.<\/a> “Arbele’s journey, including
\nstarting from invention at the University of Hong Kong and entering into
\nclinical trials at Queen Mary Hospital, fits both criteria, and we look forward
\nto continued partnership with AFCR.”<\/p>\n
\nwas a pleasure to represent Arbele throughout the BRACE Award Venture
\nCompetition process,” noted Chief Development Officer Dennis
\nWong, MD.<\/a> “The program and its committees, investment
\nand other benefits have already helped further develop our company and the application
\nof our technology in the fight against cancer.”<\/p>\n
\nVenture Competition and infusion of investment into its winner, AFCR aims to
\nraise awareness of the importance of accelerating commercialization of cancer
\nresearch innovations that could save patients’ lives,” said Asian Fund for Cancer
\nResearch Chief Executive Officer Sujuan Ba, Ph.D.<\/a> “We also hope to build up critically
\nneeded ecosystems helping life sciences entrepreneurs throughout the
\nAsia-Pacific region.”<\/p>\n
\nVenture Competition is an important addition to our region’s cancer technology
\nand biomedical industry environment, fostering ideas and approaches on the
\ncutting edge of research,” expressed AFCR Chairman of the Board<\/a> Gary Wong<\/a>, a partner of Hugill &
\nIp Solicitors<\/a>.
\n“Few sources are willing to invest in high risk, pre-clinical start-ups and,
\nthrough the BRACE program, our organization is proud to be in the lead.”<\/p>\n
\nNational Foundation for Cancer Research and AIM-HI Accelerator Fund are
\nfounding partners of the BRACE Award Venture Competition. Inaugural partners
\nare Hugill & Ip Solicitors, Goodwin and the Hong Kong Biotechnology
\nOrganization. Applications are now open for the 2021 iteration of the event, the
\nwinner of which will also receive US$300,000 in AFCR investment.<\/p>\n
\nmore about the 2021 BRACE Award Venture Competition and apply before 15 June at
\nhttps:\/\/afcr.org\/en\/brace-award\/<\/a>.<\/p>\n<\/p><\/div>\n\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"